Definium Therapeutics Set to Unveil Phase 3 Anxiety Drug Trial Results
Event summary
- Definium Therapeutics will announce topline results from its Phase 3 Panorama study of DT120 (lysergide) ODT for generalized anxiety disorder (GAD) on September 14, 2026.
- The study enrolled 245 participants across 32 centers, evaluating efficacy and safety over a 12-week double-blind treatment period.
- Primary endpoint is change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12.
- Definium Therapeutics trades on Nasdaq under the symbol DFTX.
The big picture
Definium Therapeutics is at the forefront of applying scientific rigor to psychedelics for psychiatric disorders. The Phase 3 results will be critical in determining the viability of DT120 as a potential treatment for generalized anxiety disorder, a market with significant unmet needs. Success could position Definium as a leader in the emerging psychedelic therapeutics space, while failure may necessitate a pivot in strategy.
What we're watching
- Regulatory Pathway
- Whether the DEA reschedules lysergide-containing products, which could impact commercialization timelines.
- Clinical Efficacy
- How the topline results compare to existing GAD treatments and their potential to differentiate DT120 in the market.
- Market Positioning
- The pace at which Definium can scale manufacturing and distribution if the results are positive.